Pennsylvania is currently home to 3305 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Adult Patient Outcomes After Spine Surgery with Fibergraft BG Putty/Viper Prime
NCT06704906
Recruiting
The Viper Prime/Expedium spine systems are intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of acute and chronic instabilities or deformities of the thoracolumbar and sacral spine. The Fibergraft Bioactive Glass (BG) is engineered to mimic the body's natural bone healing process. While previous studies have compared the use of Viper prime/Expedium spine system in minimally invasive and open surgeries, t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Spondylolisthesis, Lumbar Region, Spinal Trauma with Neurological Deficit, Degeneration of Lumbar Intervertebral Disc
Register for Updates
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
NCT06586255
Recruiting
The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Urothelial Carcinoma Bladder, Bladder Cancer
Register for Updates
EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment
NCT06386874
Recruiting
This is a multicenter study that will be conducted at approximately 20 centers and up to 30 centers, if the sample size will be increased following interim assessment. The Q Therapeutic System (BQ 3.0) is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. The Q Therapeutic System (BQ 3.0) is in... Read More
Gender:
ALL
Ages:
Between 22 years and 80 years
Trial Updated:
01/08/2025
Locations: Moss Rehabilitation Research Institute, Elkins Park, Pennsylvania
Conditions: Ischemic Stroke
Register for Updates
Transforming Hemodialysis-Related Vascular Access Education
NCT05997875
Recruiting
The focus of this study is on vascular access for hemodialysis. This is a randomized clinical trial testing 3 educational approaches to help patients with advanced chronic kidney disease prepare for placement of hemodialysis vascular access. Study participants will each be assigned to one of the 3 approaches: 1) "Education", in which participants will be given a video and brochure that provide information about the types of vascular access and what can be expected before and after the vascular a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Chronic Kidney Disease, Hemodialysis Vascular Access
Register for Updates
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
NCT05958342
Recruiting
The CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) Trial is a proposed 4 year, double-blind, mutli-center, prehospital and early in hospital phase randomized trial designed to determine the efficacy and safety of prehospital calcium and early in hospital vasopressin in patients at risk of hemorrhagic shock.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/08/2025
Locations: Allegheny Health Network, Pittsburgh, Pennsylvania
Conditions: Trauma, Hemorrhage
Register for Updates
MicroRNA Biomarkers for Neonatal Opioid Withdrawal Syndrome
NCT05937594
Recruiting
Infants with neonatal abstinence syndrome (NAS) experience prolonged hospital stays and poor neurodevelopmental outcomes, in-part because of the lack of accurate, individualized, biologic assessments available to manage this increasingly common medical condition. The proposed study will define the molecular mechanisms that regulate the response to opioid withdrawal in the developing brain by focusing on three candidate microRNAs (let-7a, miR-146a, miR-192) that have been shown to respond to opio... Read More
Gender:
ALL
Ages:
Between 1 day and 5 days
Trial Updated:
01/08/2025
Locations: Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Neonatal Opioid Withdrawal Syndrome, Neonatal Abstinence Syndrome
Register for Updates
Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
NCT05482789
Recruiting
This study is being done to study how exenatide, an FDA-approved drug that lowers blood sugar in non-pregnant patients with type II diabetes, works in pregnant women. To do this, the investigators will study the drug's pharmacokinetics (what the body does to the drug; specifically, how quickly your body breaks down and excretes exenatide) and pharmacodynamics (what the drug does to the body; specifically, how effectively exenatide helps the participants' pancreas secrete insulin and how well it... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
01/08/2025
Locations: Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania
Conditions: Gestational Diabetes
Register for Updates
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM
NCT05168423
Recruiting
This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with EGFR-amplified glioblastoma, IDH-wildtype that has recurred following prior radiotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Glioblastoma
Register for Updates
Evaluation of Outcome Metrics in Alexander Disease
NCT02714764
Recruiting
The purpose of this study is to define the natural history of Alexander Disease, a leukodystrophy that causes neurological dysfunction. Investigators will obtain clinical outcome assessments to measure how the disease affects a patient's gross motor, fine motor, speech and language function, swallowing, and quality of life. Specimens are collected to measure glial fibrillary acidic protein (GFAP) levels in cerebrospinal fluid (CSF) and blood. The data obtained from this study will be used for th... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/08/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Alexander Disease
Register for Updates
FAPI-74 PET/CT in Adults with Fibrosis
NCT06413355
Recruiting
This protocol is intended as a basket protocol designed to evaluate the use of Fibroblast Activating Protein (FAP) PET/CT in imaging the presence of fibrosis caused by a variety of medical conditions where fibrosis is believed to lead to pathological effects and poor prognosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
01/07/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Fibrosis (Morphologic Abnormality)
Register for Updates
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
NCT05642182
Recruiting
The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Temple University, Philadelphia, Pennsylvania
Conditions: Psoriasis
Register for Updates
Descemet Endothelial Thickness Comparison Trial I
NCT05289661
Recruiting
Descemet Endothelial Thickness Comparison Trial (DETECT) I is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 160 patients in a 2x2 factorial design. The purpose of this study is to determine differences in visual outcomes between two types of corneal transplant surgeries, ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) and Descemet membrane endothelial keratoplasty (DMEK), and to determine the effect of rho-kinase inhibitors on e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Fuchs
Register for Updates